FEMASYS INC
Close on Oct 19, 2026
- Market cap
- $5.47M
- P/E (TTM)
- –
- Dividend yield
- –
About Femasys
Surgical & Medical Instruments & Apparatus, SIC 3841
Femasys Inc. is a biomedical company specializing in women’s healthcare solutions. The company develops and commercializes in-office therapeutic and diagnostic products designed to address unmet needs in reproductive health, permanent contraception, and cancer screening. Its product offerings include FemaSeed, an intratubal insemination treatment for infertility; FemVue, FemVue Controlled, and FemChec, which are diagnostic ultrasound contrast systems for evaluating fallopian tube patency; FemSperm kits for semen preparation and analysis; and FemCerv, a tissue sampler for cervical cancer diagnosis. Femasys is also developing FemBloc, a non-surgical permanent birth control system. Its operations primarily serve healthcare providers, such as gynecologists, reproductive endocrinologists, and infertility centers, as well as their patients.
The company operates its own manufacturing and assembly facility and distributes its products across multiple global markets, including the United States, Europe, the United Kingdom, Canada, Israel, Australia, and New Zealand. Femasys maintains commercial operations and distribution partnerships in North America and Europe. The company is headquartered in Suwanee, Georgia.
Summary of the business section of Femasys's latest annual report, written by StockData.
Company profile
Company
- Legal name
- FEMASYS INC
- Headquarters
- Suwanee, GA
- Address
- 3950 Johns Creek Court, Suite 100 30024
- Phone
- (770) 500-3910
- Employees
- 51, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- FEMY
- Exchange
- Nasdaq
- IPO date
- Jun 21, 2021
- Shares outstanding
- 8M, Aug 13, 2026
- Public float
- $29.87M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Jun 8, 2026; 1-for-20 reverse, Jun 5, 2026
- SEC CIK
- 1339005
- CUSIP
- 31447E204
- ISIN
- US31447E2046
- EIN
- 11-3713499
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kathy Lee-Sepsick | Chief Executive Officer, Director | 87,848 |
| Dov Elefant | Chief Financial Officer | 15,625 |
| Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | 1,411 |
| John Charles Canning | Chief Operating Officer | 4,375 |
| Jeremy Alexander Sipos | Chief Technology Officer | 3,125 |
| Kelley Stinson Nicholas | Chief Commercial Officer | 125 |
| Daniel Scott Currie | Chief Operating Officer | 109,240 |
| Christine E. Thomas | Chief Reg & Clinical Officer | – |
| Kenneth D. Eichenbaum | Director | 25,010 |
| Charles Larsen | Director | 56 |
| Edward R. Uzialko | Director | 1,217,406 |
| Alistair Milnes | Director | – |
| Joshua Silverman | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 51 full-time employees and 3 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 15, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 21, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 18, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 23, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 15, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 2, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 21, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 14, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |